Puma Biotechnology and Medison Pharma partner to commercialize NERLYNX

In a bid to commercialize NERLYNX, Puma Biotechnology and Medison Pharma have forayed into an exclusive licensing agreement in Israel as it is currently not approved for commercialization outside U.S.  NERLYNX was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX.

Medison holds accountable for seeking the entailed  regulatory approval and, once approved, for commercializing NERLYNX in Israel. Puma will receive upfront and milestone payments throughout the term of this agreement.

Alan H. Auerbach, Chief Executive Officer and President of Puma stated “Our new agreement with Medison demonstrates our commitment to bringing NERLYNX to patients around the world while continuing to focus our commercial resources on the U.S. market.”